EXEL 250516 41.00C(EXEL250516C41000) Stock Price Today

US OptionsDetailed Quotes

EXEL250516C41000

Watchlist

0.26
-0.04-13.33%

15min DelayClose May 9 16:00 ET

0.28High0.26Low

Intraday

5D
Daily

News

Earnings Preview: Exelixis to Report Financial Results Post-market on May 13
Moomoo NewsMay 7 21:00 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
ExelixisMay 7 00:00 ET
Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Simply Wall StMay 4 10:36 ET
Top Gap Ups and Downs on Wednesday: SAN, SBUX, MDLZ and More
Moomoo NewsApr 30 18:00 ET · Markets
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
TipRanksApr 30 04:18 ET · Ratings
Press Release: Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Dow JonesApr 29 16:06 ET

Comments

Teddy123

Mar 26 21:20

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

$Exelixis (EXEL.US)$
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers

Teddy123

Mar 26 12:44

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

$Exelixis (EXEL.US)$
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data

IH TRADER

Mar 1 07:44

What You Need to Know About Exelixis and Its Stock”

1.On February 21, 2025, Exelixis announced the implementation of a $500 million stock repurchase program, expected to be completed by the second quarter of 2025. This move has boosted investor confidence and driven an increase in the company’s stock price.
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...

Teddy123

Feb 17 13:33

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at

$Exelixis (EXEL.US)$
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed

Peter Koh

Feb 15 14:00

$Exelixis (EXEL.US)$ Time to